Payment overview · 2025
General Payments
$25,221.67
24 reported records · 4 companies
Healthcare provider profile · identity verified
Scott Stuart Brehaut, MD
Allopathic & Osteopathic Physicians|Family Medicine · CLINTON, NY · NPI 1245253541
Verified facts
What the public records show
CMS Open Payments records show Scott Stuart Brehaut, MD received $25,221.67 in general payments during 2025 across 24 reported records.
Chiesi USA, Inc. accounted for 54.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Qulipta, Ubrelvy, Xcopri.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $13,657.34 | 54.1% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $11,416.06 | 45.3% | 13 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$125.00 | 0.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.27 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $22,500.00 | 9 |
| Travel and Lodging | $2,090.80 | 5 |
| Food and Beverage | $630.87 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CLEVIPREX Normalized: cleviprex |
Drug | Chiesi USA, Inc. | $13,657.34 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $8,520.56 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $6,706.05 | 9 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Xarelto | Rivaroxaban | 810 | 190 |
| Atorvastatin Calcium | Atorvastatin Calcium | 582 | 165 |
| Gabapentin | Gabapentin | 397 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 358 | 85 |
| Escitalopram Oxalate | Escitalopram Oxalate | 337 | 79 |
| Clopidogrel | Clopidogrel Bisulfate | 297 | 82 |
| Donepezil Hcl | Donepezil Hcl | 263 | 63 |
| Omeprazole | Omeprazole | 254 | 61 |
| Memantine Hcl | Memantine Hcl | 245 | 57 |
| Sertraline Hcl | Sertraline Hcl | 245 | 57 |
| Alprazolam | Alprazolam | 243 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 227 | 58 |
| Trazodone Hcl | Trazodone Hcl | 218 | 60 |
| Losartan Potassium | Losartan Potassium | 216 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 196 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 173 | 28 |
| Methylphenidate Hcl | Methylphenidate Hcl | 170 | 41 |
| Potassium Chloride | Potassium Chloride | 166 | 45 |
| Lisinopril | Lisinopril | 165 | 48 |
| Metformin Hcl | Metformin Hcl | 163 | 45 |
| Bupropion Xl | Bupropion Hcl | 159 | 35 |
| Torsemide | Torsemide | 151 | 42 |
| Famotidine | Famotidine | 143 | 39 |
| Celecoxib | Celecoxib | 140 | 41 |
| Tramadol Hcl | Tramadol Hcl | 138 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 41 |
| Furosemide | Furosemide | 124 | 37 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 117 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 34 |
| Lacosamide | Lacosamide | 107 | 25 |
| Levetiracetam | Levetiracetam | 106 | 34 |
| Glimepiride | Glimepiride | 99 | 27 |
| Mirtazapine | Mirtazapine | 98 | 23 |
| Montelukast Sodium | Montelukast Sodium | 98 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 97 | 25 |
| Carvedilol | Carvedilol | 97 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 24 |
| Azithromycin | Azithromycin | 83 | 53 |
| Diazepam | Diazepam | 83 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 83 | 17 |
| Eliquis | Apixaban | 81 | 21 |
| Midodrine Hcl | Midodrine Hcl | 81 | 17 |
| Ozempic | Semaglutide | 81 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 26 |
| Valsartan | Valsartan | 76 | 19 |
| Lorazepam | Lorazepam | 71 | 16 |
| Prednisone | Prednisone | 71 | 24 |
| Propranolol Hcl | Propranolol Hcl | 70 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 69 | 15 |
| Synthroid | Levothyroxine Sodium | 67 | 14 |
| Topiramate | Topiramate | 67 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 63 | 19 |
| Baclofen | Baclofen | 62 | 16 |
| Allopurinol | Allopurinol | 61 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 59 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 15 |
| Clonazepam | Clonazepam | 56 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 15 |
| Pregabalin | Pregabalin | 55 | suppressed |
| Risperidone | Risperidone | 53 | 12 |
| Ramipril | Ramipril | 52 | 13 |
| Meloxicam | Meloxicam | 46 | 14 |
| Methylprednisolone | Methylprednisolone | 46 | 39 |
| Simvastatin | Simvastatin | 45 | 15 |
| Nifedipine Er | Nifedipine | 44 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 32 |
| Briviact | Brivaracetam | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 29 |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 11 |
| Cephalexin | Cephalexin | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 19 |
| Nurtec Odt | Rimegepant Sulfate | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Atenolol | Atenolol | 37 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 14 |
| Januvia | Sitagliptin Phosphate | 37 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 11 |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Klor-Con M20 | Potassium Chloride | 35 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Ubrelvy | Ubrogepant | 35 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 34 | 24 |
| Jardiance | Empagliflozin | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Creon | Lipase/Protease/Amylase | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Nystatin | Nystatin | 32 | 19 |
| Sucralfate | Sucralfate | 32 | 14 |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 21 |
| Finasteride | Finasteride | 30 | suppressed |
| Brilinta | Ticagrelor | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | 11 |
| Colestipol Hcl | Colestipol Hcl | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Ondansetron Odt | Ondansetron | 26 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | 13 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 21 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 13 |
| Erythromycin | Erythromycin Base | 20 | suppressed |
| Alprazolam Er | Alprazolam | 19 | suppressed |
| Ssd | Silver Sulfadiazine | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Glipizide Er | Glipizide | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Trulance | Plecanatide | 16 | suppressed |
| Xcopri | Cenobamate | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Droxidopa | Droxidopa | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Horizant | Gabapentin Enacarbil | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $25,221.67 · 24 records | Chiesi USA, Inc. | CLEVIPREX, QULIPTA, UBRELVY, Veozah, XCOPRI | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Qulipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error